Neurogene Inc (NGNE)

$11.49 +0.72 (6.69%)
Market Cap 171.55M
Revenue (ttm) 930,000.00
Net Income (ttm) -75.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -8,079.57%
Debt to Equity Ratio 0.00
Volume 190,000
Avg Vol 280,262
Day's Range N/A - N/A
Shares Out 14.93M
Stochastic %K 91%
Beta 1.46
Analysts Strong Sell
Price Target $44.40

Latest News on NGNE

Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome

Apr 2, 2025, 4:01 PM EDT - 18 days ago

Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome

Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates

Mar 24, 2025, 4:10 PM EDT - 27 days ago

Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates

Neurogene to Participate in Upcoming Conferences

Feb 24, 2025, 7:30 AM EST - 7 weeks ago

Neurogene to Participate in Upcoming Conferences

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Neurogene Inc. (NGNE) And Encourages Shareholders to Reach Out

Nov 28, 2024, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Neurogene Inc. (NGNE) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Neurogene Inc. (NGNE) and Encourages Shareholders to Learn More About the Investigation

Nov 27, 2024, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Neurogene Inc. (NGNE) and Encourages Shareholders to Learn More About the Investigation

Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Nov 26, 2024, 10:00 AM EST - 5 months ago

Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Shareholders to Inquire about Securities Investigation

Nov 25, 2024, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Neurogene Inc. (NGNE) And Encourages Investors to Connect

Nov 24, 2024, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Neurogene Inc. (NGNE) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Stockholders to Inquire about Securities Investigation

Nov 22, 2024, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Neurogene Inc. (NGNE) and Encourages Investors to Learn More About the Investigation

Nov 21, 2024, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Neurogene Inc. (NGNE) and Encourages Investors to Learn More About the Investigation

Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Nov 20, 2024, 10:00 AM EST - 5 months ago

Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates

Nov 18, 2024, 5:25 PM EST - 5 months ago

Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates

Bronstein, Gewirtz & Grossman, LLC Is Investigating Neurogene Inc. (NGNE) And Encourages Stockholders to Connect

Nov 18, 2024, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Neurogene Inc. (NGNE) And Encourages Stockholders to Connect

Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

Nov 18, 2024, 6:45 AM EST - 5 months ago

Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Nov 17, 2024, 10:00 AM EST - 5 months ago

Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Neurogene Inc. (NGNE) and Encourages Stockholders to Learn More About the Investigation

Nov 15, 2024, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Neurogene Inc. (NGNE) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Investors to Inquire about Securities Investigation

Nov 14, 2024, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Neurogene Inc. (NGNE) And Encourages Investors to Reach Out

Nov 13, 2024, 11:30 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Neurogene Inc. (NGNE) And Encourages Investors to Reach Out

Neurogene Stock Tanks After Adverse Event In Early-Stage Rett Syndrome Gene Therapy Trial

Nov 12, 2024, 11:25 AM EST - 5 months ago

Neurogene Stock Tanks After Adverse Event In Early-Stage Rett Syndrome Gene Therapy Trial

Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

Nov 11, 2024, 4:01 PM EST - 5 months ago

Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

Neurogene Announces Oversubscribed $200 Million Private Placement

Nov 4, 2024, 7:30 AM EST - 5 months ago

Neurogene Announces Oversubscribed $200 Million Private Placement

Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome

Oct 21, 2024, 7:30 AM EDT - 6 months ago

Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome

Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates

Aug 9, 2024, 7:30 AM EDT - 9 months ago

Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates

Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome

Aug 7, 2024, 7:30 AM EDT - 9 months ago

Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome

Neurogene to Participate in BMO Genetic Medicines Summit

Jul 2, 2024, 7:30 AM EDT - 10 months ago

Neurogene to Participate in BMO Genetic Medicines Summit

Neurogene Announces Addition to Russell 3000® Index

Jul 1, 2024, 7:30 AM EDT - 10 months ago

Neurogene Announces Addition to Russell 3000® Index

Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

Jun 18, 2024, 9:26 AM EDT - 10 months ago

Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program

Jun 3, 2024, 7:30 AM EDT - 11 months ago

Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program

Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates

May 10, 2024, 7:30 AM EDT - 1 year ago

Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates

Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting

May 7, 2024, 6:19 AM EDT - 1 year ago

Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting

Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting

Apr 22, 2024, 4:36 PM EDT - 1 year ago

Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting

Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates

Mar 18, 2024, 4:14 PM EDT - 1 year ago

Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates

Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial

Mar 4, 2024, 7:30 AM EST - 1 year ago

Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial

Neurogene to Participate in Upcoming Investor Conferences

Feb 29, 2024, 7:30 AM EST - 1 year ago

Neurogene to Participate in Upcoming Investor Conferences

Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer

Jan 16, 2024, 7:00 AM EST - 1 year ago

Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer

Neurogene Announces Business Update and 2024 Outlook

Jan 5, 2024, 7:00 AM EST - 1 year ago

Neurogene Announces Business Update and 2024 Outlook

Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million

Dec 19, 2023, 7:00 AM EST - 1 year ago

Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million

Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split

Dec 14, 2023, 7:00 PM EST - 1 year ago

Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split

Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split

Sep 22, 2023, 8:00 AM EDT - 1 year ago

Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split

NEOLEUKIN THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Neoleukin Therapeutics, Inc. - NLTX

Jul 25, 2023, 10:49 AM EDT - 1 year ago

NEOLEUKIN THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Neoleukin Therapeutics, Inc. - NLTX